Proteogenomics identifies anticancer targets

RESEARCH HIGHLIGHT 25 July 2024

Targeted cancer therapies, directed at specific proteins required for tumour cell growth and survival, have proven to be an effective and precise treatment for certain types of cancer. To expand the landscape of anticancer protein targets, Savage et al. analyse Clinical Proteomic Tumor Analysis Consortium (CPTAC) proteogenomics data — including mutation, copy-number variation, DNA methylation, and transcript, protein, and phosphosite abundance data — from 1,043 treatment-naive tumour samples and 524 normal tissue samples spanning ten different cancer types, and integrate this data with other public datasets.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscription info for Chinese customers

We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout